Labomar exceeds 100 million revenue

It is a record balance sheet, exceeding 100 million in revenue for the first time, the one that will be submitted to Labomar's next Annual General Meeting, scheduled for 24 April 2024 in first call (7 May 2024 in second call if necessary).

The Board of Directors of Labomar, a leading international nutraceutical company specialising in the research, development and third-party production of food supplements, medical devices, foods for special medical purposes and cosmetics, has approved the draft financial statements and consolidated financial statements as at 31 December 2023, as well as the impact report for the year 2023 as a Beneficial Company: the figures show significantly growing results both in terms of turnover, which stands at EUR 103.6 million (+12.8 points compared to the 2022 financial year) and in terms of margins.

A result to which all Group companies contribute, including the latest acquisitions: 'For the first time in our history we have surpassed the one hundred million revenue threshold, almost doubling our turnover in just four years,' comments CEO and founder Walter Bertin. 'A record, considering the complexities of the current economic and geopolitical context, as well as the changing dynamics of supply chains and the profound transformations also affecting the world of work. Looking to the future, 2024 marks a 'new beginning' for our Group. While remaining anchored to our long-standing values, such as a passion for wellness, customer relations, and a drive for innovation, we are ready to take on new challenges. Thanks to the partnership with a partner of primary standing such as Charterhouse and to the strengthening of the management team, we will go back to evaluating possible further acquisitions as part of an articulated growth plan, both organic and by external lines".

Labomar's path of growth by external lines began in 2019 with the acquisition of Labomar Canada, and continued in 2022 with the Welcare Group in Umbria and Labiotre in Tuscany. Each of these entities has added value to the Group, strengthening the control of the supply chain in the nutraceutical sector. "Labomar demonstrated excellent organic growth in 2023, confirming its role as a leader and innovator in the nutraceutical sector. In addition, also thanks to the strengthening of the team we are now ready to seize important growth opportunities through acquisitions in Europe and North America, further consolidating Labomar's leadership in the sector," adds Antonio Di Lorenzo, partner at Charterhouse one of the oldest private equity firms operating in Europe, which joined Labomar in 2023.

During the financial year 2023, the integration between the companies started to show results. The parent company Labomar Spa recorded a turnover of EUR 79.4 million, accounting for approximately 77% of the total revenue. Compared to 2022, all Group companies recorded double-digit growth. At the same time, the number of employees also increased: on 31 December 2023, there were 407 employees, an increase of 13% compared to the previous year.